Zhi‐Cheng Jin

机构：Zhongshan Hospital · ORCID：0000-0002-6114-154X

发表论文 33 篇 · 总被引 905 次 · h-index 14

代表论文

• Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001) (2023 · Signal Transduction and Targeted Therapy · 被引 294)
• Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study (2024 · EClinicalMedicine · 被引 154)
• Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study (2023 · European Radiology · 被引 90)
• Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma (2022 · Journal of Clinical and Translational Hepatology · 被引 74)
• Machine-learning analysis of contrast-enhanced computed tomography radiomics predicts patients with hepatocellular carcinoma who are unsuitable for initial transarterial chemoembolization monotherapy: A multicenter study (2021 · Translational Oncology · 被引 40)
• Application of 18F-FDG PET-CT Images Based Radiomics in Identifying Vertebral Multiple Myeloma and Bone Metastases (2022 · Frontiers in Medicine · 被引 21)